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Abstract
Clostridium difficile is the primary cause of antibiotic associated diarrhea in humans and is a significant cause of morbidity
and mortality. Thus the rapid and accurate identification of this pathogen in clinical samples, such as feces, is a key step in
reducing the devastating impact of this disease. The bacterium produces two toxins, A and B, which are thought to be
responsible for the majority of the pathology associated with the disease, although the relative contribution of each is
currently a subject of debate. For this reason we have developed a rapid detection assay based on microwave-accelerated
metal-enhanced fluorescence which is capable of detecting the presence of 10 bacteria in unprocessed human feces within
40 seconds. These promising results suggest that this prototype biosensor has the potential to be developed into a rapid,
point of care, real time diagnostic assay for C. difficile.
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Introduction
Clostridium difficile is a spore forming, toxin-producing
bacterium which is currently the principal cause of healthcare
associated diarrhea in the western world. In the USA in 2007 there
were 284 875 infections while in the UK during the same period
the pathogen was linked to the death of 8 324 individuals [1,2].
The bacterium currently presents a considerable challenge to
healthcare professionals and has stimulated researchers to develop
improved diagnostics and medical countermeasures.
In healthy individuals the spore form of the bacterium is carried
in the gut with no ill effects. Subsequent disruption of the gut flora,
usually by broad spectrum antibiotics, enables the bacterium to
proliferate and release two toxins, a 308 kDa enterotoxin (toxin A)
and a 270 kDa cytotoxin (toxin B) which are responsible for
symptoms ranging from mild diarrhea to fatal colitis [3].
The genes encoding the production of these toxins, tcdA and
tcdB, are located within a 19.6 kb pathogenicity locus (PaLoc)
which is present in all toxin producing strains [4–6]. The relative
contribution of each toxin to pathogenicity is currently a subject of
debate and thus the ability to detect the presence of both would
greatly enhance diagnostic capability [7,8].
The current gold standard for C. difficile diagnosis is the cell
cytotoxin neutralization assay (CCTA) which can only detect toxin
B, has 99–100% specificity and 85–100% sensitivity, and takes
between 48–72 hours to generate a result [3,9]. To reduce the
time for detection, other methods have been developed such as
enzyme immunoassays (EIAs) which detect toxins A and B, and
glutamate dehydrogenase [9,10]. These assays are easy to perform
and give rapid results (15–20 minutes); however, they currently
suffer from low sensitivity [11–14].
DNA methods based on the Real Time Polymerase Chain
Reaction (RT PCR) have been developed to detect the genes
associated with toxin production and the current commercially
available systems, the ProGastro assay (Cepheid Smart Cycler),
GeneXpert (Cepheid), and the BD Gene Ohm assay, all target
toxin B [15,16]. Although these assays are highly sensitive they are
labor intensive and costly due to the need to include a purification
step to remove inhibitory biological materials [11,16–18].
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A new platform technology called microwave-accelerated metal-
enhanced fluorescence (MAMEF) has recently been developed
which eliminates the need for extensive sample purification. The
approach has been successfully employed to detect a range of
human pathogens including Bacillus anthracis, Salmonella
typhimurium and Chlamydia trachomatis [19–22]. The approach
combines two technologies, metal enhanced fluorescence (MEF) to
optically amplify fluorescence signatures and low power micro-
wave heating to accelerate the reaction kinetics of the assay.
Combined together they yield a system with a level of sensitivity
comparable to RT PCR, but with a much shorter turnaround time
of ,60 seconds, and at a significantly lower cost.
The underlying principal of the technology is based on the
selective heating of water, whereby the aqueous medium is heated
via microwave power. As the metal is not heated, a temperature
gradient between the cold metal surface and the warm aqueous
solution is formed, which facilitates mass transport to the surface
and allows DNA, or other biomarkers, to be recognized when the
assay is complete and the fluorophore is in close proximity to the
metal [22]. Non-radiative energy transfer occurs between fluor-
ophores and plasmon electrons in a non-continuous film. The
metal surface itself radiates the coupled fluorescence quanta [23].
As a consequence the assay does not require the prior removal of
organic material such as blood and feces and is thus able to
directly detect the presence of a bacterial target in clinical samples.
A system capable of detecting the presence of C. difficile spores
in patient feces within 5 minutes would represent a considerable
improvement over current capabilities. Such a system could
potentially impact on the quality of clinical care as early treatment
would limit disease progression and reduce cross transmission to
other patients.
In this paper we describe our efforts to develop a MAMEF
based system capable of detecting C. difficile spores in human
feces. Using DNA probes specific to toxin A and B we were able to
detect a few as 10 spores in 500 ml of unprocessed human feces
within 40 seconds, suggesting that this approach has the potential
to be developed into a rapid point of care, real time diagnostic
assay.
Materials and Methods
Bacterial Strains, growth conditions and genomic DNA
C. difficile strain CD630 was obtained for culture from the
NCTC, Public Health England, UK. BHI agar and broth (Oxoid;
Remel Inc, KS, USA) supplemented with 0.1% of the bile salt
sodium taurocholate (Sigma Aldrich, USA) was used for routine
culture of C. difficile at 37uC in a 3.4 L anaerobic jar (Oxoid, UK)
with an anaerobic gas generating kit (Oxoid, UK). Phosphate
buffered saline (PBS; Sigma Aldrich, USA) constituting 0.01 M
phosphate buffer, 0.0027 M potassium chloride and 0.137 M
sodium chloride was made by dissolving 1 tablet in 200 ml diH2O.
Human feces was provided by a healthy volunteer. Genomic DNA
(gDNA) from C. difficile strain CD630 (5 mg) was obtained from
ATCC, USA as a control.
Genomic DNA Extraction from C. difficile using Chelex
100
Genomic DNA was extracted from C. difficile and other species
(Table S1; Table S2) as described previously [24].
C. difficile toxin A and B Probe Design
Probes were designed to recognize nucleotide sequences within
conserved regions of toxins A and B. As part of the design process
we incorporated features which would enable us to utilize the
probes in a future MAMEF assay. The anchor probe for the C.
difficile assay was designed to be 17 nucleotides in length and to be
separated from the 22 nucleotide fluorescent detector probe by a
stretch of 5 nucleotides. The anchor probe binds target DNA while
the detector probe subsequently binds at a distance which
positions the fluorophore optimally for biomolecular recognition
to occur [22]. The use of anchor and detector probes also allows
for two levels of sensitivity within the assay for each toxin
(Table 1).
Designed probes were tested against a representative collection
of 58 C. difficile isolates; including blood culture and variant
strains (only produced toxin B; ribotypes 017, 047, 110), obtained
from the National Anaerobic Reference Unit, Cardiff, Wales,
courtesy of Dr. Val Hall.
Preparation of DIG-labeled DNA Hybridization Probes
PCR was performed using Taq DNA polymerase core kit
(Qiagen, Crawley, United Kingdom). Hybridization probes were
labeled with the DIG (Digoxigenin) PCR dNTP labeling mix
(Roche Diagnostics, UK) in 20 ml reactions as described previously
[25]. PCR conditions are as described previously (Figure S3; Table
S2) [25]. PCR products were analyzed via gel electrophoresis on a
1% agarose gel at 85 V (Biorad Mini sub cell GT, UK).
Dot blot hybridization and macro-arraying gDNA onto a
positively charged nylon membrane
For dot blot hybridization, gDNA was macroarrayed onto a
positively charged nylon membrane using dot blot apparatus
(Figure S3; Flexys robotic workstation, Genomic Solutions Ltd,
UK). Dot blot hybridization was performed as described
previously [26,27].
Dot blots of Human Metagenomic gut DNA & Ethics
Statements
The human gut environment contains approximately 1012/g
bacteria [28]. Therefore the probes designed to detect C. difficile
must be able to specifically detect the toxin genes amongst the
numerous bacteria present. To further confirm the specificity of
the designed probes, metagenomic DNA samples from ten human
volunteers were obtained from Cardiff School of Biosciences,
Wales, Cardiff, UK, courtesy of Dr. Julian Marchesi. The
metagenome was extracted from feces from humans in Zanzibar,
Cote d’Ivoire and the UK [29,30]. Original sample collection in
the UK was approved by Cardiff University Biosciences Local
Ethics Committee as healthy samples with informed consent.
Original sample collection from Cote d’Ivoire was approved by
the ethical review boards of the ETH Zurich, Switzerland (2006–
23), the University of Basel (EKBB), Switzerland (224/06), and the
Ministry of Health in Coˆte d’Ivoire (5782/MSHP/CAB/
CNESVS/06) [29]. The original sample collection from Zanzibar
was approved by the institutional research commission of the Swiss
Tropical and Public Health Institute (Basel, Switzerland). Ethical
clearance was obtained from the Ethics Committee of the Ministry
of Health and Social Welfare (MoHSW) in Zanzibar (application
number 16) [30].
Deposition of gold triangles onto glass substrates to
microwave and lyse C. difficile
To focus the microwave power in the microwave, gold lysing
triangles were used, provided by the Institute of Fluorescence
(Figure 1). Deposition and preparation as described previously
[22].
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The release of C. difficile DNA from spores using
microwave irradiation
C. difficile (16105 cfu/ml) was suspended into PBS buffer and
500 ml added into the gold tie lysing chamber and exposed to a
15 s microwave pulse at 80% power in a GE microwave Model
No. JE2160BF01, kW 1.65 (M/W). The microwaved solution was
examined for the presence of viable organisms. Further experi-
ments involved spiking human feces diluted with PBS buffer with
varying concentrations of C. difficile and then irradiating. Each
experiment was conducted in triplicate.
Bacterial quantification after focused microwave
irradiation
Control samples (1.336107 cfu/ml) were drop counted as
described previously [31,32]. Before DNA release, samples were
heated at 80uC for 10 min to ensure removal of any vegetative
cells. After lysis the numbers of remaining viable spores (cfu/ml)
were enumerated.
Gel electrophoresis of samples
Post microwave irradiation the sample was centrifuged at
3000 g for 15 min (Heraeus Primo R; Fisher Scientific, USA) and
the supernatant resuspended in 1:2 ethanol. This supernatant was
resuspended in 100 ml sterile deionized water. Samples were
analyzed via gel electrophoresis on a 2% agarose gel at 70 V
(Biorad Mini sub cell GT, UK).
Formation of Silver Island Films (SiFs) on glass substrates
Silver island Films (SiFs) were prepared at an OD450 of 0.4–0.5
on Silane-prep glass slides (Sigma Aldrich, USA; Figure 1;
Figure 2) to enable silver adhesion, as described previously
[33,34].
Anchor and fluorescent probes and target DNA
Probes specific for conserved regions of toxin A and toxin B of
C. difficile were designed and validated (Table 1; Figures 3, 4).
Probes were modified to enable incorporation into the MAMEF
Table 1. Table of Oligonucleotides.
Toxin A Toxin B
Anchor Probe Thiol-TTTTT-TTTAATACTAACACTGC Thiol-TTTTTT-CAAGACTCTATTATAG
Capture Probe Alexa-488-TGTTGCAGTTACTGGATGGCAA Alexa-594-TAAGTGCAAATCAATATGAAG
Synthetic
oligonucleotides
AAATTATGATTGTGACGTAATCCCAATACAACGTCAATGACCTACCGTT AGTTCTGAGATAATATCTAATCCCAATATTCACGTTTAGTTATACTTG
Anchor and capture probes, and synthetic oligonucleotides target regions used in the MAMEF assay for toxins A and B are shown, along with the corresponding
fluorophore used.
doi:10.1371/journal.pone.0104334.t001
Figure 1. Gold lysing triangle on Starfrost slide and a typical Silver Island Film (SiFs). (A) Gold triangle with silicone isolators added to
create lysing chamber. (B) The SiF here is at an OD450 of 0.43 and has multi-well silicone isolators added. Each well can hold an individual DNA assay
reaction; hence multiple repeats can be conducted.
doi:10.1371/journal.pone.0104334.g001
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detection platform (Figure 2); a thiol group was added to the 59
region of the anchor probe to enable binding of the DNA to the
surface of the SiF while the capture probe was labelled with an
Alexa (Invitrogen, USA) fluorophore [20,21]. The Alexa fluor-
ophore 488 (green) was used to label toxin A and the Alexa
fluorophore 594 (red) was used to label toxin B. These
fluorophores were chosen due to their wavelength separation
and thus yield two different fluorescence emissions upon excita-
tion. The common regions in the anchor probes were preceded by
5 consecutive thymine bases, included to increase the flexibility of
the probe once bound to the silver surface, and enhanced by the
inclusion of a C at the 39 terminal to which a thiol group was
subsequently added [20]. The negative strand of the target region
was also synthesised to bind to the capture and anchor probes as a
synthetic control sample (Figure S1; Figure S2; Invitrogen, USA).
Preparation of MAMEF assay platform for detection of C.
difficile DNA
Glass slides with SiFs deposited were coated with self-adhesive
silicone isolators as described previously [21]. The thiolated
anchor probe was then covalently bound to the SiF in a self
assembled monolayer chemistry [35]. This was achieved by
diluting 40 mM anchor probe into 100 ml of 1 M Tris- EDTA
buffer and adding 9 ml to 250 mM of 20 ml dithiothreitol. The
mixture was incubated at room temperature for 60 min. The
anchor probe (1 mM) was diluted into 4 ml Tris- EDTA buffer and
100 ml of the anchor probe was added to and incubated in each
well of the SiF for 75 min. After incubation the anchor was
removed and 50 ml of 1 mM Alexa-Fluor probe was added to 50 ml
of DNA from the target organism. The SiFs containing the bound
probes and DNA were then incubated by heating for 25 s in a
microwave cavity at 20% power, GE microwave Model
No. JE2160BF01, 1.65 kiloWatts. Only in the presence of target
DNA the three piece assay is complete and enhanced-fluorescence
can be observed (Figure 2). The sample was removed from the
well after MAMEF and the well washed with 100 ml TE buffer 3
times. Each experiment was conducted in triplicate.
Detection and fluorescence spectroscopy
The presence of target DNA was confirmed by the generation of
a fluorescent signal following excitation with laser light. Fluores-
cence was emitted by the DNA MAMEF capture assay and
measured using a Fiber Optic Spectrometer (HD2000) (Ocean
Optics, Inc) by collecting the emission intensity (I).
Statistical Analysis
Statistical analysis was performed using GraphPad Prism
version 5.04 for Windows, (GraphPad Software, La Jolla
California USA, www.graphpad.com). Three replicates were
performed for each detection experiment. Statistical significant
Figure 2. Schematic configuration of 3 piece DNA detection assay. This configuration was used for detection of both toxin A and toxin B
probes. The anchor probe (17 oligonucleotides) was anchored to the SiFs by addition of the thiol group. The fluorescent probe (22 oligonucleotides)
was attached to an Alexa at the 39 end. Upon hybridization with target DNA, the 3 piece assay is formed, and the fluorophore labeled probe is
plasmon enhanced.
doi:10.1371/journal.pone.0104334.g002
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differences were tested for using one way analysis of variance
(ANOVA) at the 95% confidence interval in conjunction with a
Kruskall-Wallis test. Dunnett’s post test was employed to compare
sample data to control data. A P value of,0.05 was considered
significant [36].
Results
Specificity of DNA probes for Toxin A and Toxin B
detection as determined via dot blot
DNA probes were designed to recognize sequences within
conserved regions of the gene sequences of toxin A and B and were
configured to take account of the requirements of the MAMEF
Figure 3. Detection of target DNA within various concentrations of gDNA by MAMEF. Various concentrations of C. difficile gDNA (strain
CD630; ATCC, USA) were tested in the MAMEF platform. Concentrations of 10 ng and 5 ng were microwave irradiated for 8 seconds at 70% power.
gDNA was subjected to disruption to increase the chances of the detection probes accessing the toxin specific sequences. The data presented is the
result from a single reproduced assay. (A) The fluorescent signal intensities generated from toxin A detection within microwaved gDNA (excitation at
495 nm, emission at 519 nm). (B) The fluorescent signal intensities generated from toxin B detection within gDNA (excitation at 590 nm, emission at
617 nm). The control was PBS buffer.
doi:10.1371/journal.pone.0104334.g003
Figure 4. Electrophoresis gel of DNA released from C. difficile spores and vegetative cells following different periods of microwave
treatment. C. difficile spores at a concentration of 16105 cfu/ml, in combination with gold triangles, were exposed to 80% microwave power for
periods ranging from 8 to 16 seconds (Lanes 2–10). Lane M shows the 1 kilobase molecular weight DNA marker ladder. Lane 1 shows control non-
microwaved bacteria.
doi:10.1371/journal.pone.0104334.g004
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assay. Genomic DNA from 58 clinical isolates of C. difficile,
representing a diverse range of ribotypes, was macroarrayed as
shown in Figure S3. As expected each strain which contained a
copy of the toxin A and B gene sequences gave a positive signal,
the strength of which varied between isolates, likely due to an
artifact of the experimental procedure. To confirm the specificity
of the probes, variant isolates of C. difficile lacking toxin A
(ribotypes 017; 047: tcdA2tcdB+) or toxin B (Toxinotype XIa; XIb;
DS1684: tcdA2tcdB2) gene sequences were included in the panel.
The DNA from each of these isolates was not recognized by the
relevant probe.
To further confirm the specificity of the probes genomic DNA
from other bacterial species, both close and distant relatives were
subject to hybridization analysis (Figure S4; Table S2). The probes
did not bind to bacterial species unrelated to C. difficile, further
indicating that the probes were highly specific to toxins A and B of
C. difficile. Species of the Clostridium genus, including species
closely related to C. difficile (which possess toxins closely related to
tcdB) did not show any probe hybridization which further validates
probe specificity. We further confirm the specificity of these probes
by demonstrating that they were unable to recognise metagenomic
DNA from the human gut flora of ten healthy human volunteers
(July 2011). Based on these results we concluded that the probes
were highly specific and thus were suitable for inclusion in a
MAMEF- based detection assay.
Detection of toxin A and B sequences in genomic DNA
isolated from C. difficile using the MAMEF assay
After confirming the specificity of the toxin A and B probes,
their ability to bind to toxin gene sequences in the context of the
MAMEF assay was assessed. gDNA isolated from a known toxin
producing strain of C. difficile (CD630) was suspended in PBS
buffer and subjected to microwave fragmentation for 8 seconds at
70% total microwave power [GE microwave Model No. -
JE2160BF01, kW 1.65 (M/W)]. DNA was subjected to disruption
to increase the chances of the detection probes accessing the toxin
specific sequences. Untreated gDNA in PBS was included as a
control. Both sets of toxin specific probes were able to detect 10 ng
of intact and disrupted gDNA (Figure 3A & B). The intensity of
the signals generated against gDNA at emissions wavelengths of
519 nm (toxin A) and 617 nm (toxin B) were similar to those seen
for synthetic oligonucleotide targets (Figures S1; S2) suggesting
that microwave treatment is an efficient means of generating
probe target DNA.
Release of DNA from C. difficile spore preparations using
focused microwave irradiation
Bacterial gDNA is normally sequestered within the body of the
host organism, making it difficult for detection probes to gain
access. The process is more complicated with bacteria such as B.
anthracis and C. difficile which have the ability to form spores.
Thus we employed a microwave based approach, previously
developed to release DNA from B. anthracis spores, to break open
the spore and vegetative form of C. difficile to release target DNA
[20]. This approach employs gold triangles with a 1 mm gap to
focus microwaves which rapidly heat the spores leading to their
physical disruption. Thus 500 ml aliquots comprising 16105 cfu/
ml of C. difficile spores suspended in PBS were subjected to
microwave radiation for periods between 2 and 16 seconds, and
then analyzed for DNA release via gel electrophoresis. Exposure to
microwaves for 15 seconds at 80% total microwave power resulted
in optimal release of DNA, with the majority of DNA disrupted to
produce fragments between 50–200 bp in size (Figure 4). In
contrast, irradiation for 16 seconds resulted in further fragmenta-
tion of DNA and yielding fragments too small to be detected by
the toxin probes.
Bacterial quantification following focused microwave
irradiation
To confirm that microwave irradiation had resulted in
disruption of bacterial structure and that the DNA detected did
not simply represent free-floating extracellular DNA, the effect of
microwave treatment on bacterial viability was determined.
Exposure to microwaves for 15 seconds resulted in a 99%
reduction in viable spore numbers from 1.336107 cfu/ml to
3.676103 cfu/ml.
Detection of target DNA in spores of C. difficile
suspended in PBS
Spores of C. difficile CD630 were suspended in PBS and
microwaved for 15 seconds at 80% power. Following treatment,
the cell suspension was diluted to give a range of bacterial
concentrations (Figure 5A & B). At the highest spore concentra-
Figure 5. Detection of DNA frommicrowaved C. difficile spore preparation in PBS using MAMEF. Spores of C. difficile from strain CD630 at
a range of concentrations 10, 100, 1000 and 10 000 cfu were suspended in PBS and subjected to microwave irradiation and screened for the presence
of toxin A and toxin B using MAMEF. (A) Various fluorescent signal intensities generated from detection of toxin A within gDNA from irradiated spores
(excitation at 495 nm, emission at 519 nm). (B) The various fluorescent signal intensities generated from detection of toxin B within gDNA from
irradiated spores (excitation at 590 nm, emission at 617 nm).
doi:10.1371/journal.pone.0104334.g005
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tion tested, 10000 cfu, the toxin A and B probes gave signals of 15
AU (519 nm) and 15 AU (617 nm) respectively. The lowest
concentration of spores tested, 10 cfu, also gave detectable signals
with both probes- (toxin A 12 AU, toxin B 10 AU).
Detection of spores of C. difficile in human feces
Spores of C. difficile CD630 were suspended in human feces
and microwaved for 15 seconds at 80% power. Prior to treatment,
the spore suspension was diluted to give a range of bacterial
concentrations (Figure 6A & B). At 1000 cfu, the toxin A and B
probes gave signals of 23 AU (519 nm) and 19 AU (617 nm)
respectively. The lowest concentration of spores tested, 10 cfu, also
gave detectable signals with both probes- 15 AU (519 nm) and 13
AU (617 nm).
Discussion
In this communication we describe the development of a bench
top assay based on MAMEF which is capable of detecting as few
as 10 bacteria of C. difficile in a fecal sample within 40 seconds.
To put this into context, during infection patients excrete between
10 000 to 10 000 000 spores per gram of feces [37].
Thus, in addition to detecting active infection, the assay could
also be used to identify patients who carry small numbers of C.
difficile in their gut but are asymptomatic. The C. difficile
asymptomatic carriage rate in humans varies between 4–20% and
treatment of these individuals with broad spectrum antibiotics
could precipitate an active infection [38]. Therefore information
concerning the presence or absence of the bacterium in a patient’s
gut would assist the clinician in determining the most appropriate
treatment option for that individual.
The level of sensitivity and speed of this prototype assay
compares favorably with all of the currently available C. difficile
detection methods [39]. The sensitivity of assays within the C.
difficile detection market range from 90–100% for the cell
cytotoxin, EIAs and PCR assays; however, to increase the
sensitivity and accuracy of diagnosis these assays are employed
in algorithms [40].
The ability of the assay to directly detect the pathogen in the
presence of fecal material is a major advantage over other DNA
based methods. Current PCR based assays can take between 2–
8 hrs to generate a result; due in part to the need to remove
enzyme inhibitors in feces which can prevent the amplification of
target DNA [9]. In contrast, the MAMEF assay does not employ
an enzymic amplification step and thus can operate in the
presence of organic material such as blood and feces [22,41]. This
is due to the low power microwave acceleration which increases
the rate of DNA hybridization within the biological sample via
metal enhanced fluorescence; whereby the SiF amplifies the
fluorescence of the labeled reporter DNA [42].
A further advantage of this prototype assay is its ability to detect
the genes encoding both toxins A and B. The contribution of both
toxins to the pathology of the infection is currently a subject of
debate [8,43]. Until relatively recently it was thought that only
toxin B was essential for virulence. As a consequence commercial
PCR based methods such as BD Gene Ohm and Xpert Cepheid
are configured to detect only toxin B [44]. Given this uncertainty,
the ability to detect both toxins would provide an obvious
advantage until the relative importance of each toxin has been
clarified.
To realize the potential of our promising technology, future
studies will focus on optimizing the MAMEF platform. This will
involve the development of an integrated microwave and laser
platform miniaturization, reduced power signature and a simple
readout would need to be incorporated into a hand held device
capable of being used at the bedside. Studies are already in
progress to multiplex the assay and thus detect the presence of
both toxins A and B in a single sample well.
We believe our prototype C. difficile detection assay has the
potential to be developed into a real-time assay capable of
identifying infected and colonized individuals within 40 seconds.
Such an assay would fulfill the pressing need for a rapid and
sensitive detection system capable of detecting both toxin A and B.
In the future we believe this assay could be used as a means of
screening patients upon admission to hospital to enable appropri-
ate treatment regimens and clinical management decisions to be
made.
Supporting Information
Figure S1 Detection of various concentrations of syn-
thetic oligonucleotide in TE buffer by MAMEF. The
Figure 6. Detection of DNA from lysed C. difficile in feces using MAMEF. Spores of C. difficile from strain CD630 at a range of concentrations
10, 100, and 1000 cfu were suspended in human feces and subjected to microwave irradiation, then screened for the presence of toxin A and toxin B
using MAMEF. (A) The various fluorescent signal intensities generated from detection of toxin A within gDNA from irradiated spores of C. difficile in
human feces (excitation at 495 nm, emission at 519 nm). (B) Graph demonstrating the fluorescent signal intensities generated from detection of toxin
B within gDNA from irradiated spores of C. difficile in human feces (excitation at 590 nm, emission at 617 nm).
doi:10.1371/journal.pone.0104334.g006
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concentration of anchor probe attached to the silver island film
surface for toxin A was 10 nM, whereas for toxin B the anchor
concentration was 100 nM. Thus there is variation in the signal
intensity generated from the toxin A and toxin B probes. A range
of synthetic oligonucleotide concentrations from 1 nM to
100 000 nM were used to determine the ability of the probes to
fluoresce in response to excitation via laser light. The fluorescent
intensity data presented in the above graphs is the result from a
single reproduced assay (A) Graph demonstrating the various
fluorescent signal intensities of a range of toxin A synthetic
oligonucleotides bound to the toxin A anchor and detector probes.
(B) Real color photographs of the fluorescent signal produced at
each concentration from the sample wells. The laser light used to
excite the fluorescent toxin A probe was at a wavelength of
495 nm excitation which produced an emission at 519 nm. (C)
Graph demonstrating the various fluorescent signal intensities of a
range of toxin B synthetic oligonucleotides bound to the toxin B
anchor and detector probes. (D) Real color photographs of the
fluorescent signal produced at each concentration from the sample
wells. The laser light used to excite the fluorescent toxin B probe
was at a wavelength of 590 nm excitation which produced an
emission at 617 nm.
(TIF)
Figure S2 Detection of various concentrations of syn-
thetic oligonucleotides in feces by MAMEF. Human feces
was diluted by 50% in PBS and mixed with the synthetic target
concentrations and tested in the MAMEF platform. The
concentration of anchor probe attached to the silver island film
surface for toxin A and toxin B was 10 nM. A range of synthetic
oligonucleotide concentrations from 1 nM to 1000 nM were used
to determine the ability of the probes to fluoresce in response to
excitation via laser light. The fluorescent intensity data presented
in the above graphs is the result from a single assay which was
repeated three times. (A) Graph demonstrating the various
fluorescent signal intensities of a range of toxin A synthetic
oligonucleotides bound to the toxin A anchor and detector probes
in the presence of human feces. (B) Graph demonstrating the
various fluorescent signal intensities of a range of toxin B synthetic
oligonucleotides bound to the toxin B anchor and detector probes
in the presence of human feces.
(TIF)
Figure S3 Dot blot of hybridization of C. difficile gDNA.
Genomic DNA from the panel of 58 C. difficile isolates tested were
macroarrayed as shown (3A+B) and tested against our DIG-
labeled probes. To confirm probe specificity, variant isolates of C.
difficile (tcdA2tcdB+) lacking either the toxin A (ribotypes 017;
047: tcdA2tcdB+) or toxin B (Toxinotype XIa; XIb; DS1684:
tcdA2tcdB2) gene sequences were included. DNA from these
isolates did not bind to the probes. (C) tcdA76 anchor probe (D)
tcdA76 detector probe, (E) tcdB anchor probe (F) tcdB detector
probe vs. C. difficile isolates. Bromophenol blue+ lambda phage
DNA was added to the first well orientate the membrane.
(TIF)
Figure S4 Dot blot of related and unrelated bacterial
species by DNA hybridization. Species related and unrelated
to C. difficile were tested against the probes for specificity. There
was no hybridization of the probes to the gDNA on the
membrane. Positive control for each probe was CD630 and a
variant strain control R22680 (tcdA2tcdB+) was also included. (A)
tcdA50 anchor probe, (B) tcdA50 detector probe, (C) tcdA76
anchor probe, (D) tcdA76 detector probe, (E) tcdB anchor probe,
(F) tcdB detector probe.
(TIF)
Table S1 Table of isolates used in this study. The isolates
of C. difficile are listed. Panel also includes 21 isolates as described
previously [30]. Isolates from blood culture are listed as (B/C).
Toxin production for each strain and its PCR ribotype are shown,
with additional information including the source. The isolates and
information above was provided courtesy of Dr. Jon Brazier and
Dr. Val Hall at the Anaerobic Reference Unit, University Hospital
Wales, Cardiff, UK, 2008.
(TIF)
Table S2 Additional bacterial species used in this study.
The additional species and their strain designations used in this
study are listed above. The species related to, and those not related
to, C. difficile are shown. The species were obtained from the
NTCC (National Type Culture Collection, HPA, London, UK),
unless otherwise stated. Other isolates obtained from the anaerobic
reference unit (ARU) at the University Hospital Wales (UHW) are
listed as ARU, UHW. Those isolates and information was
provided courtesy of Dr. Jon Brazier and Dr. Val Hall at the
Anaerobic Reference Unit, University Hospital Wales, Cardiff,
UK.
(JPG)
Table S3 PCR Thermocycle annealing temperatures
per probe. The probes for each toxin were found to have the
above optimal temperatures for PCR to occur. These are the
temperature at which all further PCR reactions and dot blot
reactions were conducted.
(TIF)
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